International Stem Cell CORP (ISCO) stock
ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026Market cap $2.27MP/E –Yield –
International Stem Cell r&d expenses
Research and development expenses are spending on new products and technology.
International Stem Cell's R&D Expenses for the twelve months ending Jun 30, 2026 was $646.00K, down 13.4% year over year. For fiscal 2025 it was $684.00K, up 4.1% from the year before. Over ten years it grew -12.9% a year on average. The highest annual figure on record is $5.39M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $684.00K | +4.1% |
| FY2024 | Dec 31, 2024 | $657.00K | +28.6% |
| FY2023 | Dec 31, 2023 | $511.00K | +3.9% |
| FY2022 | Dec 31, 2022 | $492.00K | -29.2% |
| FY2021 | Dec 31, 2021 | $695.00K | -29.7% |
| FY2020 | Dec 31, 2020 | $988.00K | -28.7% |
| FY2019 | Dec 31, 2019 | $1.39M | -42.2% |
| FY2018 | Dec 31, 2018 | $2.40M | -9.9% |
| FY2017 | Dec 31, 2017 | $2.66M | -6.9% |
| FY2016 | Dec 31, 2016 | $2.86M | +5.5% |
| FY2015 | Dec 31, 2015 | $2.71M | -49.7% |
| FY2014 | Dec 31, 2014 | $5.39M | +51.3% |
| FY2013 | Dec 31, 2013 | $3.56M | -1.1% |
| FY2012 | Dec 31, 2012 | $3.60M | -18.8% |
| FY2011 | Dec 31, 2011 | $4.43M | +31.4% |
| FY2010 | Dec 31, 2010 | $3.37M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $155.00K | -4.3% |
| Q1 FY2026 | Mar 31, 2026 | $156.00K | -16.6% |
| Q4 FY2025 | Dec 31, 2025 | $177.00K | -15.7% |
| Q3 FY2025 | Sep 30, 2025 | $158.00K | -15.5% |
| Q2 FY2025 | Jun 30, 2025 | $162.00K | +95.2% |
| Q1 FY2025 | Mar 31, 2025 | $187.00K | +5.6% |
| Q4 FY2024 | Dec 31, 2024 | $210.00K | +26.5% |
| Q3 FY2024 | Sep 30, 2024 | $187.00K | +20.6% |
| Q2 FY2024 | Jun 30, 2024 | $83.00K | +84.4% |
| Q1 FY2024 | Mar 31, 2024 | $177.00K | +22.1% |
| Q4 FY2023 | Dec 31, 2023 | $166.00K | +32.8% |
| Q3 FY2023 | Sep 30, 2023 | $155.00K | +5.4% |
| Q2 FY2023 | Jun 30, 2023 | $45.00K | -45.8% |
| Q1 FY2023 | Mar 31, 2023 | $145.00K | +5.8% |
| Q4 FY2022 | Dec 31, 2022 | $125.00K | +10.6% |
| Q3 FY2022 | Sep 30, 2022 | $147.00K | -31.6% |
| Q2 FY2022 | Jun 30, 2022 | $83.00K | -63.9% |
| Q1 FY2022 | Mar 31, 2022 | $137.00K | -46.3% |
| Q2 FY2021 | Jun 30, 2021 | $113.00K | -43.5% |
| Q1 FY2021 | Mar 31, 2021 | $215.00K | -29.0% |
| Q4 FY2020 | Dec 31, 2020 | $230.00K | -40.3% |
| Q3 FY2020 | Sep 30, 2020 | $255.00K | +222.8% |
| Q2 FY2020 | Jun 30, 2020 | $200.00K | -25.4% |
| Q1 FY2020 | Mar 31, 2020 | $303.00K | -53.6% |
| Q4 FY2019 | Dec 31, 2019 | $385.00K | -25.5% |
| Q3 FY2019 | Sep 30, 2019 | $79.00K | -87.2% |
| Q2 FY2019 | Jun 30, 2019 | $268.00K | -40.7% |
| Q1 FY2019 | Mar 31, 2019 | $653.00K | -19.5% |
| Q4 FY2018 | Dec 31, 2018 | $517.00K | -14.4% |
| Q3 FY2018 | Sep 30, 2018 | $616.00K | -8.1% |
| Q2 FY2018 | Jun 30, 2018 | $452.00K | -38.8% |
| Q1 FY2018 | Mar 31, 2018 | $811.00K | +25.7% |
| Q4 FY2017 | Dec 31, 2017 | $604.00K | -19.0% |
| Q3 FY2017 | Sep 30, 2017 | $670.00K | -1.3% |
| Q2 FY2017 | Jun 30, 2017 | $739.00K | -13.3% |
| Q1 FY2017 | Mar 31, 2017 | $645.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $746.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $679.00K | – |
| Q2 FY2016 | Jun 30, 2016 | $852.00K | – |
See a number that looks wrong?